FDA-cleared test solves the preeclampsia diagnostic conundrum
30 Sept 2024
After losing her second child to preeclampsia at 36 weeks of gestation, Yolanda Carrillo sought expert care before trying again. Discover how a new preeclampsia test helped provide the critical answers she needed when complications arose during her third pregnancy.
About the company
Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
